| IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY | |
| Goods/Services | Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use |
|---|---|
| Owner |
Bristol-Myers Squibb Company Bristol-Myers Squibb Company 345 Park Avenue New York, NY 10154 United States |
| Status | Serial number was assigned in error. Please do not use this number to identify any application. You will receive a "Notice of Incomplete Trademark Application" explaining why the serial number was held "misassigned." |
| Filed | 0000-00-00 |
| Registered | 0000-00-00 |
| Serial No |
US77775341
Check with the respective trademark agency at the link above for the most up-to-date information on mark status, owner, and address for service. |
IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
